This advancement facilitates recognition of highly sensitive markers of cancer targets like proteins [PSA, human epidermal growth factor receptor 2 (HER2), and cancer antigen 125 (CA-125)], genetic materials (DNA and miRNA), and extracellular components such as exosomes and circulating tumor cells [194, 195]. Here, ERBB2 is linked to neoplasm.